BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9553671)

  • 1. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil.
    Iop A; Cartei G; Isaia A
    Ann Oncol; 1998 Feb; 9(2):225-7. PubMed ID: 9553671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
    Gebbia V; Mantovani G; Agostara B; Contu A; Farris A; Colucci G; Cognetti F; Restivo G; Speciale R; Ferrero B
    Ann Oncol; 1995 Dec; 6(10):987-91. PubMed ID: 8750150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study.
    Moroni M; Giannetta L; Gelosa G; Secondino S; Chillura G; Colombo E; Siena S
    J Chemother; 2003 Aug; 15(4):394-9. PubMed ID: 12962369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Gebbia V; Valenza R; Testa A; Borsellino N; Cannata G; Restivo S; Speciale R; Ingria F; Spadafora G; Gebbia N
    ORL J Otorhinolaryngol Relat Spec; 1994; 56(5):279-82. PubMed ID: 7526312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
    Amrein PC; Fabian RL
    Laryngoscope; 1992 Aug; 102(8):901-6. PubMed ID: 1379664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
    Clavel M; Vermorken JB; Cognetti F; Cappelaere P; de Mulder PH; Schornagel JH; Tueni EA; Verweij J; Wildiers J; Clerico M
    Ann Oncol; 1994 Jul; 5(6):521-6. PubMed ID: 7522527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study.
    Gebbia V; Mantovani G; Farris A; Agostara B; Desogus A; Curreli L; Moschella F; Di Gregorio C; Bajetta E; Gebbia N
    Cancer; 1997 Apr; 79(7):1394-400. PubMed ID: 9083162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
    Tellez-Bernal E; Belehradek M; Recondo G; Cvitkovic E; Leridant AM; Vericel R; Armand JP
    Am J Clin Oncol; 1990 Oct; 13(5):452-4. PubMed ID: 1699403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck.
    Gebbia V; Testa A; Di Gregorio C; Ingria F; Valenza R; Cannata G; Moschella F; Restivo G; Gebbia N
    Am J Clin Oncol; 1995 Aug; 18(4):293-6. PubMed ID: 7625368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternating combination chemotherapy using cisplatin-bleomycin with sequential methotrexate-5-FU plus leucovorin rescue in patients with head and neck cancer.
    Panasci L; Gravenor D; Black M; Frenkiel S; Margolese R
    Cancer Treat Rep; 1985 Sep; 69(9):1015-7. PubMed ID: 2411401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Espinosa E; Zamora P; Millá A; Morales S; Molina R; Mira M; González Barón M;
    Head Neck; 2002 Dec; 24(12):1054-9. PubMed ID: 12454943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
    Recondo G; Armand JP; Tellez-Bernal E; Domenge C; Belehradek M; De Vathaire F; Wibault P; Richard JM; Cvitkovic E
    Laryngoscope; 1991 May; 101(5):494-501. PubMed ID: 1709437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDDP and 5-FU after prior VBM or VBM after prior CDDP and 5-FU in the management of recurrent squamous cell carcinoma of the head and neck?
    Grimaldi A; Merlano M; Gardin G; Rosso R
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1539-40. PubMed ID: 2439343
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck.
    Abele R; Honegger HP; Grossenbacher R; Mermillod B; Kaplan E; Gervasi A; Wolfensberger M; Lehmann W; Cavalli F
    Eur J Cancer Clin Oncol; 1987 Jan; 23(1):47-53. PubMed ID: 2439344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
    Dimery IW; Legha SS
    J Clin Oncol; 1986 Nov; 4(11):1670-6. PubMed ID: 3095503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Forastiere AA; Metch B; Schuller DE; Ensley JF; Hutchins LF; Triozzi P; Kish JA; McClure S; VonFeldt E; Williamson SK
    J Clin Oncol; 1992 Aug; 10(8):1245-51. PubMed ID: 1634913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.